|
Sharing Data From FDA Reviews Is Next ‘Frontier’ of Agency Transparency
Devicemakers and the rest of the scientific community can and should benefit from the careful disclosure of FDA review data that industry and the agency currently keep closely guarded, FDA Commissioner Margaret Hamburg says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives